In vitro activity of moxifloxacin compared to other fluoroquinolones against different erythromycin-resistant phenotypes of group A beta-hemolytic streptococcus.
The aim of the present study was to evaluate the in vitro activity of moxifloxacin (BAY 12-8039) compared to ciprofloxacin, ofloxacin and sparfloxacin against 156 group A beta-hemolytic Streptococcus strains. Sixty strains were macrolide-, lincosamide- and streptogramin-B-susceptible; 16 strains exhibited a constitutive resistance phenotype; 32 strains exhibited an inducible phenotype, and 48 strains were characterized by the M-type efflux-dependent phenotype. The minimum inhibition concentrations were determined by an agar dilution method according to NCCLS-approved guidelines. Moxifloxacin showed an enhanced activity compared with the other fluoroquinolones against the different macrolide-resistant phenotypes.
Esposito
S
S
Clinica Malattie Infettive, Seconda Università degli Studi di Napoli, Italia. silvanoesposito@mail.dex-net.com
Noviello
S
S
Ianniello
F
F
Novelli
A
A
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000890:Anti-Infective Agents / Q000494:pharmacology*; D001372:Aza Compounds; D002648:Child; D004305:Dose-Response Relationship, Drug; D004352:Drug Resistance, Microbial; D004917:Erythromycin / Q000494:pharmacology*; D024841:Fluoroquinolones; D006801:Humans; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D010641:Phenotype; D011804:Quinolines; D013297:Streptococcus pyogenes / Q000187:drug effects* / Q000302:isolation & purification
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D004917:Erythromycin; D000077266:Moxifloxacin